Intralesional MMR Vaccine Shows Promise for Treating Resistant Pediatric Warts

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-09-15T09:45:39+05:30 | Updated On 13 Feb 2024 1:00 AM IST

USA: Warts are a common skin condition, especially among children, and while various treatments are available, some warts can be particularly stubborn and resistant to conventional therapies. A recent retrospective study has explored the potential of using the measles, mumps, and rubella (MMR) vaccine as an alternative treatment for pediatric warts that have failed to respond to initial therapy with Candida antigen.

The study included 51 pediatric patients with warts that had proven resistant to intralesional Candida antigen therapy. These patients were then treated with intralesional injections of the MMR vaccine. The results were encouraging, with 15.5% of the patients experiencing complete resolution of their warts. Additionally, 12% had a near-complete resolution, and 37% showed partial improvement.

One interesting finding from the study was that age seemed to play a role in treatment response. Patients under the age of 12 were more likely to respond positively to the MMR vaccine treatment. However, the number of MMR treatments did not significantly affect treatment response.

While this study has its limitations, such as its retrospective nature and relatively small sample size, it suggests that the intralesional MMR vaccine could be a viable and effective treatment option for pediatric warts that do not respond to conventional therapies. The findings also highlight the importance of exploring alternative treatments for stubborn skin conditions, particularly in cases where existing therapies have been ineffective.

This study suggests that the intralesional MMR vaccine could offer hope for patients dealing with stubborn pediatric warts. It emphasises the importance of exploring alternative treatments when initial therapies fail and highlights the potential benefits of early intervention, especially in younger patients. Further research may provide more insights into optimising this approach for the effective management of warts in children.

Reference:

Ulschmid, C. M., Patel, J., Pan, A. Y., Liegl, M., & Holland, K. E. (2023). Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts. Pediatric Dermatology. https://doi.org/10.1111/pde.15415

Pediatric DermatologyMMR vaccineintralesional immunotherapymeasles mumps and rubella vaccinepediatric warts

Source : Pediatric Dermatology

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751